There are 383 resources available
Introduction
Presenter: Marina Garassino
Session: ESMO Colloquium supported by Eli Lilly and Co. - One tumour, many faces: Optimising testing, targeting and monitoring oncogene-addicted NSCLC beyond EGFR
Resources:
Slides
Webcast
Tissue testing for actionable biomarkers in patients with advanced NSCLC: Scientific and implementation perspectives and the positioning of molecular tumour boards
Presenter: Fernando Lopez-Rios
Session: ESMO Colloquium supported by Eli Lilly and Co. - One tumour, many faces: Optimising testing, targeting and monitoring oncogene-addicted NSCLC beyond EGFR
Resources:
Slides
Webcast
An overview of molecular epidemiology of rare molecular aberrations and matching treatment strategies for patients with non-EGFR, oncogene-addicted advanced NSCLC
Presenter: Fabrice Barlesi
Session: ESMO Colloquium supported by Eli Lilly and Co. - One tumour, many faces: Optimising testing, targeting and monitoring oncogene-addicted NSCLC beyond EGFR
Resources:
Slides
Webcast
Live Q&A / discussion
Session: ESMO Colloquium supported by Eli Lilly and Co. - One tumour, many faces: Optimising testing, targeting and monitoring oncogene-addicted NSCLC beyond EGFR
Resources:
Webcast
Concluding remarks
Presenter: Fernando Lopez-Rios
Session: ESMO Colloquium supported by Eli Lilly and Co. - One tumour, many faces: Optimising testing, targeting and monitoring oncogene-addicted NSCLC beyond EGFR
Resources:
Webcast
Case presentation - A patient with ALK+ NSCLC: How clinical characteristics, biopsy specimen and cfDNA can guide treatment decisions
Presenter: Laura Mezquita
Session: More targets, more drugs, more choices, more conflicts
Resources:
Slides
Webcast
Integrated testing: The challenges we now face
Presenter: Keith Kerr
Session: More targets, more drugs, more choices, more conflicts
Resources:
Slides
Webcast
Targeted therapy and immunotherapy: Can the patient have both?
Presenter: Anne-Marie Dingemans
Session: More targets, more drugs, more choices, more conflicts
Resources:
Slides
Webcast
Co-mutations: Impact on current treatments and new combinations
Presenter: Pilar Garrido Lopez
Session: More targets, more drugs, more choices, more conflicts
Resources:
Slides
Webcast
Rebiopsy and cfDNA in a complex and changing landscape
Presenter: Nicola Normanno
Session: More targets, more drugs, more choices, more conflicts
Resources:
Slides
Webcast